Centre Hospitalier Pasteur

At Centre Hospitalier Pasteur in Colmar, clinical research is focused on neoplasms, with a strong emphasis on non-small cell lung cancer. The studies are designed to explore better treatment options for patients with advanced disease and for those whose cancer has been completely removed but still carries a risk of returning.

• Evaluating a new adjuvant therapy approach for patients with completely resected stage IB, II, and IIIA non-small cell lung cancer
• Assessing treatment effectiveness in advanced ROS1-positive lung cancer after prior targeted therapy

These trials aim to improve disease-free survival and identify more effective options for patients with specific molecular features of lung cancer.

The research program at Service de Médecine F includes studies in oncology that focus on the biology and treatment of advanced ROS1-positive non-small cell lung cancer. This work looks at how patients respond after earlier targeted treatments and seeks to refine care for distinct molecular subgroups.

• Testing a targeted therapy strategy for ROS1-positive NSCLC after progression on first-line treatment
• Improving outcomes for patients with resected stage IB, stage II, and stage IIIA NSCLC

The overall goal is to support more precise treatment selection and strengthen long-term control of lung cancer through better use of molecular analysis and immunotherapy-based research.